Dr. James Croop

Pediatrics
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 

Overview

James Croop is a Pediatrics provider practicing medicine in Indianapolis, Indiana.

His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Pineocytoma, Osteosarcoma, and Ewing Sarcoma.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 16 clinical trials.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in IN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Riley Hospital for Children at Indiana University Health
705 Riley Hospital Dr, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Croop has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone
Study Phase: Phase 1
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
Enrollment Status: Completed
Publish Date: July 15, 2024
Intervention Type: Biological, Other
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Other
Study Drug: Entinostat
Study Phase: Phase 1
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

13 Total Publications

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
Journal: Pediatric blood & cancer
Published: November 21, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Rosalia Misseri
Pediatrics
Expertise in
30
conditions
Dr. Rosalia Misseri
Pediatrics

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-944-8896
Languages Spoken:
English
See accepted insurances

Rosalia Misseri is a Pediatrics provider practicing medicine in Indianapolis, Indiana. Dr. Misseri is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Neurogenic Bladder, Hypospadias, Bowel Incontinence, Reconstructive Urology Surgery, and Lithotripsy.

Expertise in
29
conditions
Dr. Joshua Roth
Pediatrics
Expertise in
29
conditions
Dr. Joshua Roth
Pediatrics

Office

575 Riley Hospital Dr Ste 1210, 
Indianapolis, IN 
 (1.0 miles away)
317-944-8896
Languages Spoken:
English
See accepted insurances

Joshua Roth is a Pediatrics provider practicing medicine in Indianapolis, Indiana. Dr. Roth is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Neurogenic Bladder, Neurogenic Bowel, Hypospadias, Ureteral Reconstruction, and Knee Replacement.

Expertise in
31
conditions
Dr. Martin Kaefer
Pediatrics
Expertise in
31
conditions
Dr. Martin Kaefer
Pediatrics

Office

702 Barnhill Dr Ste 4230, 
Indianapolis, IN 
 (1.0 miles away)
317-278-1021
Languages Spoken:
English
See accepted insurances

Martin Kaefer is a Pediatrics provider practicing medicine in Indianapolis, Indiana. Dr. Kaefer is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Ureterocele, Hypospadias, Neurogenic Bladder, Reconstructive Urology Surgery, and Bladder Reconstruction.

Frequently Asked Questions about Dr. James Croop

How do I make an appointment with Dr. James Croop?

You can book an appointment with Dr. James Croop by calling their office at 317-944-2143. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Croop a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Croop is classified as an Experienced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Croop specialize in?

While Dr. James Croop is a Pediatrics, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Pineocytoma, and Osteosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. James Croop participate in research or clinical trials?

Yes. Dr. James Croop has published 13 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. James Croop's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James Croop accept my insurance?

Dr. James Croop accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 317-944-2143 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Croop's expertise for a condition
ConditionClose
        View All 23 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile